Karyopharm Tapped Lori Macomber Of Legend Biotech As CFO, Effective January 3
Karyopharm Tapped Lori Macomber Of Legend Biotech As CFO, Effective January 3
Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Lori Macomber as Executive Vice President, Chief Financial Officer and Treasurer, effective January 3, 2025. In this role, Ms. Macomber will be responsible for leading and directing the financial activities of the Company.
Karyopharm Therapeutics Inc. (纳斯达克:KPTI)，一家领先新型癌症治疗的商业阶段药品公司，今天宣布任命Lori Macomber为执行副总裁、首席财务官和财务主管，任职于2025年1月3日。在这个职位上，Macomber女士将负责领导和指导公司的财务活动。
Ms. Macomber has over 20 years of diversified experience in leading growth and driving financial strategies for life science companies. She has a proven track record in financial management for companies ranging from start-up to Fortune 500 and has also successfully supported various collaboration partnerships, business development activities and licensing deals. Most recently, she served as Chief Financial Officer at Legend Biotech Corporation, a publicly traded, commercial-stage biopharmaceutical company. Previously, Ms. Macomber held leadership roles of increasing responsibility with Ametek PDS, Cello Health, Eli Lilly and Company, and Pfizer (formerly Pharmacia). Ms. Macomber holds a Bachelor of Science in Accounting from Pennsylvania State University and is a Certified Public Accountant.
Macomber女士拥有超过20年的多元化经验，领导增长并推动生命科学公司的财务战略。她在从初创公司到财富500强公司的财务管理方面有着良好的业绩记录，同时还成功支持了多种合作伙伴关系、业务发展活动和许可交易。最近，她担任传奇生物公司（Legend Biotech Corporation）的首席财务官，该公司是一家上市的商业阶段生物制药公司。在此之前，Macomber女士在阿美特克（Ametek PDS）、Cello Health、辉瑞（Pfizer，前身为Pharmacia）等公司担任了越来越多的领导职务。Macomber女士获得了宾夕法尼亚州立大学的会计学理学士学位，并且是一名注册公共会计师。
